| Organism (no.) | R pattern | % Inhibited at CLSI breakpoints |
|
|---|---|---|---|
| 1997–2000 | 2002–2005 | ||
| SA (2,652) | MRSA | 22.8 | 23.0 |
| PSA (807) | IPM-R | 9.5 | 12.4 |
| Ceftazidime (CAZ)-R | 17.8 | 16.8 | |
| LEV-R | 28.2 | 26.2 | |
| Amikacin (AMK)-R | 10.4 | 5.5 | |
| EC (711) | CAZ-R | 2.2 (8.3)b | 5.7 (12.7)b |
| LEV-R | 6.5 | 12.3 | |
| ESP (338) | IPM-NSa | 0.6 | 1.7 |
| CAZ-R | 22.4 | 17.5 | |
| LEV-R | 7.5 | 6.2 | |
| KSP (283) | CAZ-R | 14.9 (20.3)b | 11.9 (20.0)b |
| LEV-R | 3.4 | 9.6 | |
| AMK-R | 1.4 | 1.5 | |
| ASP (179) | IPM-R | 7.9 | 11.5 |
| CAZ-R | 46.5 | 41.0 | |
| LEV-R | 28.7 | 30.8 | |
| AMK-R | 55.4 | 28.2 | |
a
NS, non-susceptible.
b
Number in parentheses reflects the ESBL-phenotype rate (MIC values ≥2 mg/L).